- early virological response (EVR)
A reduction in hepatitis C RNA viral load by week 12 of treatment. A partial
early virological response (pEVR) means that it has dropped by at least 2 log10 (99%). A complete early
virological response (cEVR) means that viral load is undetectable by week 12.
- effectiveness
How well something works (in real life conditions). See also ‘efficacy’.
- efficacy
How well something works (in a research study). See also ‘effectiveness’.
- encephalopathy
-
A disease or infection affecting the brain.
- end of treatment response (ETR, EOT)
An undetectable hepatitis C RNA viral load when treatment is ended. This does not necessarily mean that hepatitis C is cured – see ‘sustained virological response’.
- endogenous
-
Coming from within.
- endoscopy
-
Viewing the inside of the body cavity with a flexible instrument using fibre optics.
- endpoint
In a clinical trial, a clearly defined outcome which is used to evaluate whether a treatment is working or not. Trials usually have a single primary endpoint (e.g. having an undetectable viral load) as well as a few secondary endpoints, covering other aspects of treatment safety, tolerability and efficacy.
- end-stage liver disease (ESLD)
When the liver loses most or all of its functions, leading to liver failure.
- enteric
-
Associated with the gut.
- epidemiology
The study of the causes of a disease, its distribution within a population, and measures for control and prevention. Epidemiology focuses on groups rather than individuals.
- epidermis
-
The outer layers of the skin.
- epilepsy
A condition where someone has a tendency to have recurrent seizures (fits).
- epitope
-
The part of an antigen which the immune system recognises.
- Epstein-Barr virus
-
The virus that causes oral hairy leukoplakia and glandular fever. Sometimes called mononucleosis.
- equivalence trial
A clinical
trial which aims to demonstrate that a new treatment is no better or worse than
an existing treatment. While the two drugs may have similar results in terms of
virological response, the new drug may have fewer side-effects, be cheaper or
have other advantages. See also ‘non-inferiority trial’ and ‘superiority
trial’.
- erectile dysfunction
-
A man's inability to have or maintain an erection, also known as ED or impotence.
- erythema
-
A red skin eruption or rash.
- erythropoietin
-
A natural hormone made in the kidneys to stimulate the production of red blood cells by the bone marrow.
- ethics committee
-
A panel of people which reviews any proposed clinical trial to ensure that the participants are protected from any foreseeable exploitation or harm. In the US known as the Institutional Review Board.
- exclusion criteria
-
Reasons that would disqualify a person from joining a trial.
- exogenous
-
Coming from outside the body.
- expanded access scheme
-
A programme that allows access to an experimental drug outside clinical trials for people in particular need.
- experimental study
A
study design in which researchers provide treatment in a pre-planned,
experimental way and record the outcome. Clinical trials, such as randomised
controlled trials, are experimental studies.
- extended rapid virological response (eRVR)
An undetectable
hepatitis C RNA viral load within 4 weeks of starting treatment, maintained
until at least week 12.
- extrahepatic
Something that has an
effect outside the liver, for example when viral hepatitis affects the kidneys
or causes depression.